Incyte (INCY) News Today $68.84 +1.78 (+2.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Incyte Co. (NASDAQ:INCY) Receives $76.18 Average Price Target from BrokeragesDecember 22 at 3:34 AM | americanbankingnews.comFranklin Resources Inc. Has $13.20 Million Holdings in Incyte Co. (NASDAQ:INCY)Franklin Resources Inc. trimmed its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 19.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,718 shares of the biopharmaceutical company's sDecember 21 at 4:46 AM | marketbeat.comIncyte Co. (NASDAQ:INCY) Stock Position Lowered by Sanctuary Advisors LLCSanctuary Advisors LLC reduced its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 53.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,056 shares of the biopharmaceutical companyDecember 21 at 4:26 AM | marketbeat.comThe Analyst Verdict: Incyte In The Eyes Of 15 ExpertsDecember 20 at 2:57 PM | benzinga.comIncyte price target raised to $70 from $68 at Wells FargoDecember 20 at 2:57 PM | finance.yahoo.comIncyte (NASDAQ:INCY) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysWells Fargo & Company boosted their price objective on shares of Incyte from $68.00 to $70.00 and gave the stock an "equal weight" rating in a research report on Thursday.December 19 at 10:01 AM | marketbeat.comIncyte Co. (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from AnalystsShares of Incyte Co. (NASDAQ:INCY - Get Free Report) have been given an average rating of "Hold" by the twenty ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendatiDecember 19 at 2:44 AM | marketbeat.comThomas Tray Sells 650 Shares of Incyte Co. (NASDAQ:INCY) StockDecember 18, 2024 | insidertrades.comInsider Selling: Incyte Co. (NASDAQ:INCY) Insider Sells 650 Shares of StockIncyte Co. (NASDAQ:INCY - Get Free Report) insider Thomas Tray sold 650 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $69.31, for a total value of $45,051.50. Following the transaction, the insider now directly owns 23,312 shares of the company's stock, valued at approximately $1,615,754.72. The trade was a 2.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.December 17, 2024 | marketbeat.comIncyte’s Mixed Clinical Results and Financial Challenges Lead to Hold RatingDecember 17, 2024 | markets.businessinsider.comUBS Group Initiates Coverage on Incyte (NASDAQ:INCY)UBS Group began coverage on Incyte in a report on Tuesday. They issued a "neutral" rating and a $77.00 price target on the stock.December 17, 2024 | marketbeat.comOrion Portfolio Solutions LLC Takes Position in Incyte Co. (NASDAQ:INCY)Orion Portfolio Solutions LLC bought a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,655 shares of the biopharmaceutical company's stock, valued at approximately $770,0December 17, 2024 | marketbeat.comWellington Management Group LLP Trims Stock Position in Incyte Co. (NASDAQ:INCY)Wellington Management Group LLP reduced its position in Incyte Co. (NASDAQ:INCY - Free Report) by 59.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,730 shares of the biopharmaceutical company's stock after selling 103,09December 17, 2024 | marketbeat.comToronto Dominion Bank Purchases 7,812 Shares of Incyte Co. (NASDAQ:INCY)Toronto Dominion Bank raised its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 16.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,084 shares of the biopharmaceutical company's stock afterDecember 16, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio lessened its position in Incyte Co. (NASDAQ:INCY - Free Report) by 17.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 58,971 shares of the biopharmaceutical company's stock after selling 12,843 shares during the periDecember 16, 2024 | marketbeat.comGeode Capital Management LLC Trims Stock Holdings in Incyte Co. (NASDAQ:INCY)Geode Capital Management LLC reduced its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,936,176 shares of the biopharmaceutical coDecember 15, 2024 | marketbeat.comIncyte's (INCY) Outperform Rating Reaffirmed at William BlairDecember 15, 2024 | americanbankingnews.comIncyte (NASDAQ:INCY) Cut to "Buy" at StockNews.comDecember 15, 2024 | americanbankingnews.comIncyte’s Growth Prospects Hampered by Pipeline Setbacks and Market ChallengesDecember 14, 2024 | markets.businessinsider.comIncyte Co. (NASDAQ:INCY) Shares Sold by Vestcor IncVestcor Inc trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 86.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,625 shares of the biopharmaceutical company's stock after selling 17,167 shares duringDecember 14, 2024 | marketbeat.comNomura Asset Management Co. Ltd. Purchases 9,675 Shares of Incyte Co. (NASDAQ:INCY)Nomura Asset Management Co. Ltd. grew its position in Incyte Co. (NASDAQ:INCY - Free Report) by 14.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,955 shares of the biopharmaceutical company's stock after acquiringDecember 14, 2024 | marketbeat.comIncyte (NASDAQ:INCY) Cut to Buy at StockNews.comStockNews.com cut shares of Incyte from a "strong-buy" rating to a "buy" rating in a report on Friday.December 13, 2024 | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Incyte (NASDAQ:INCY)William Blair restated an "outperform" rating on shares of Incyte in a report on Friday.December 13, 2024 | marketbeat.com49,161 Shares in Incyte Co. (NASDAQ:INCY) Bought by Tri Ri Asset Management CorpTri Ri Asset Management Corp bought a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 49,161 shares of the biopharmaceutical company's stock, valued at approximately $3,292,000. Incyte maDecember 13, 2024 | marketbeat.comContinuum Advisory LLC Has $38,000 Stock Position in Incyte Co. (NASDAQ:INCY)Continuum Advisory LLC lessened its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 98.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 580 shares of the biopharmaceutical company's stock afDecember 13, 2024 | marketbeat.comNational Bank of Canada FI Acquires 37,809 Shares of Incyte Co. (NASDAQ:INCY)National Bank of Canada FI boosted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 86.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,728 shares of the biopharmaceutical company'December 13, 2024 | marketbeat.comTri Ri Asset Management Corp Takes Position in Incyte Co. (NASDAQ:INCY)Tri Ri Asset Management Corp acquired a new position in Incyte Co. (NASDAQ:INCY - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 49,161 shares of the biopharmaceutical company's stock, valued at apprDecember 12, 2024 | marketbeat.comBarclays PLC Grows Stake in Incyte Co. (NASDAQ:INCY)Barclays PLC raised its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 8.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,031,932 shares of the biopharmaceutical company'sDecember 12, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Teachers Retirement System of The State of KentuckyTeachers Retirement System of The State of Kentucky lowered its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 6.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 369,913 shares of the biopharmaceutical company's stock after sellingDecember 11, 2024 | marketbeat.comIncyte’s BET Inhibitor Program Holds Promise Amid Safety Concerns and Strategic UncertaintyDecember 10, 2024 | markets.businessinsider.comIncyte says Phase 3 inMIND trial met primary endpoint of PFSDecember 10, 2024 | tipranks.comIncyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular LymphomaDecember 10, 2024 | businesswire.comIncyte reports positive Phase 3 data for Zynyz for lung cancerDecember 9, 2024 | msn.comXTX Topco Ltd Sells 8,990 Shares of Incyte Co. (NASDAQ:INCY)XTX Topco Ltd trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 29.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,057 shares of the biopharmaceutical company's stock after selling 8,990 shares during the period. XTX Topco Ltd'December 9, 2024 | marketbeat.comState Street Corp Trims Stock Position in Incyte Co. (NASDAQ:INCY)State Street Corp lessened its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 2.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,551,279 shares of the biopharmaceutical company'sDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Has $11.31 Million Position in Incyte Co. (NASDAQ:INCY)Janus Henderson Group PLC lessened its position in Incyte Co. (NASDAQ:INCY - Free Report) by 6.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 171,129 shares of the biopharmaceutical company's stock after selling 11,552 shares duringDecember 9, 2024 | marketbeat.comIncyte announces results from Phase 3 trial evaluating retifanlimab in NSCLCDecember 8, 2024 | tipranks.comQuantinno Capital Management LP Has $4.49 Million Stake in Incyte Co. (NASDAQ:INCY)Quantinno Capital Management LP lifted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 106.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,968 shares of the biopharmaceuDecember 8, 2024 | marketbeat.comRoyal London Asset Management Ltd. Sells 8,163 Shares of Incyte Co. (NASDAQ:INCY)Royal London Asset Management Ltd. cut its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 174,689 shares of the biopharmaceutical company's stock after sellDecember 8, 2024 | marketbeat.comIncyte Corp (INCY) Announces Promising Results from Phase 3 POD1UM-304 TrialDecember 7, 2024 | gurufocus.comIncyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz ®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung CancerDecember 7, 2024 | investing.comIncyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung CancerDecember 7, 2024 | businesswire.comIncyte Co. (NASDAQ:INCY) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lessened its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 40.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,782 shares of the biopharDecember 6, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Fmr LLCFmr LLC lessened its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 26.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,320,469 shares of the biopharmaceutical company's stock after selling 466,December 6, 2024 | marketbeat.comIncyte gets FDA orphan designation for treatment of nodal marginal zone lymphomaDecember 5, 2024 | markets.businessinsider.comVerition Fund Management LLC Makes New Investment in Incyte Co. (NASDAQ:INCY)Verition Fund Management LLC bought a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 40,467 shares of the biopharmaceutical company's stock, valued at approximately $2,675,December 5, 2024 | marketbeat.comIncyte gains amid takeover speculationDecember 4, 2024 | msn.comIncyte Co. (NASDAQ:INCY) EVP Sells $455,521.34 in StockDecember 4, 2024 | insidertrades.comEdgestream Partners L.P. Purchases New Holdings in Incyte Co. (NASDAQ:INCY)Edgestream Partners L.P. acquired a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 22,408 shares of the biopharmaceutical company's stock, valued at approximaDecember 4, 2024 | marketbeat.comCaisse DE Depot ET Placement DU Quebec Has $331,000 Stock Holdings in Incyte Co. (NASDAQ:INCY)Caisse DE Depot ET Placement DU Quebec lowered its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 98.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,002 shares of the biopharmaceutical company's stock after selling 329,December 4, 2024 | marketbeat.com Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin INCY Media Mentions By Week INCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼0.670.60▲Average Medical News Sentiment INCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼1911▲INCY Articles Average Week Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Neurocrine Biosciences News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Exelixis News Today Repligen News Today Madrigal Pharmaceuticals News Today Halozyme Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCY Stock Alerts